São Paulo - Delayed Quote • BRL
Merck & Co., Inc. (MRCK34.SA)
At close: April 25 at 4:51 PM GMT-3
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
60,115,000.00
60,115,000.00
59,283,000.00
48,704,000.00
41,518,000.00
Cost of Revenue
16,126,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Gross Profit
43,989,000.00
43,989,000.00
41,872,000.00
35,078,000.00
27,900,000.00
Operating Expense
41,035,000.00
41,035,000.00
23,590,000.00
21,879,000.00
22,352,000.00
Operating Income
2,954,000.00
2,954,000.00
18,282,000.00
13,199,000.00
5,548,000.00
Net Non Operating Interest Income Expense
-781,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
Other Income Expense
-284,000.00
-284,000.00
-1,033,000.00
1,450,000.00
1,087,000.00
Pretax Income
1,889,000.00
1,889,000.00
16,444,000.00
13,879,000.00
5,863,000.00
Tax Provision
1,512,000.00
1,512,000.00
1,918,000.00
1,521,000.00
1,340,000.00
Net Income Common Stockholders
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Diluted NI Available to Com Stockholders
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Basic EPS
0.02
--
0.72
0.65
0.35
Diluted EPS
0.02
--
0.71
0.64
0.35
Basic Average Shares
20,296,000.00
--
20,256,000.00
20,240,000.00
20,241,806.62
Diluted Average Shares
20,376,000.00
--
20,336,000.00
20,304,000.00
20,328,000.00
Total Expenses
57,161,000.00
57,161,000.00
41,001,000.00
35,505,000.00
35,970,000.00
Net Income from Continuing & Discontinued Operation
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Normalized Income
861,910.00
861,910.00
16,278,819.00
11,470,617.41
6,590,522.00
Interest Income
365,000.00
365,000.00
157,000.00
36,000.00
59,000.00
Interest Expense
1,146,000.00
1,146,000.00
962,000.00
806,000.00
831,000.00
Net Interest Income
-781,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
EBIT
3,035,000.00
3,035,000.00
17,406,000.00
14,685,000.00
6,694,000.00
EBITDA
6,907,000.00
6,907,000.00
21,315,000.00
17,899,000.00
10,180,000.00
Reconciled Cost of Revenue
16,126,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Reconciled Depreciation
3,872,000.00
3,872,000.00
3,909,000.00
3,214,000.00
3,486,000.00
Net Income from Continuing Operation Net Minority Interest
365,000.00
365,000.00
14,519,000.00
12,345,000.00
7,067,000.00
Total Unusual Items Excluding Goodwill
-629,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Total Unusual Items
-629,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Normalized EBITDA
7,536,000.00
7,536,000.00
23,308,000.00
16,917,000.00
9,562,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-132,090.00
-132,090.00
-233,181.00
107,617.41
141,522.00
12/31/2020 - 12/28/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ABBV34.SA AbbVie Inc.
53.70
-0.28%
G1SK34.SA GSK plc
42.09
+0.05%
AMGN34.SA Amgen Inc.
49.65
0.00%
PFIZ34.SA Pfizer Inc.
32.58
-3.44%
JNJB34.SA Johnson & Johnson
50.58
-1.06%
GILD34.SA Gilead Sciences, Inc.
174.25
+0.72%
A1ZN34.SA AstraZeneca PLC
64.56
+6.18%
N1VS34.SA Novartis AG
51.00
+1.05%
BIIB34.SA Biogen Inc.
171.36
-2.16%
PNVL3.SA Dimed S.A. Distribuidora de Medicamentos
11.00
-0.45%